文献速递儿童呼吸儿童感染

胸膜腔内tPA联合DNase与单用tPA在儿童脓胸中的疗效:随机临床试验

Effectiveness of Intrapleural Tissue Plasminogen Activator and Dornase Alfa vs Tissue Plasminogen Activator Alone in Children with Pleural Empyema: A Randomized Clinical Trial.
PubMed 文献 · JAMA Pediatr · 2020-01-01

这项多中心、安慰剂对照优效性随机试验纳入97例需引流的儿童脓胸患者,比较胸膜腔内tPA联合DNase与tPA联合安慰剂。结论认为指南应继续支持单用胸膜腔内纤溶药物作为儿童脓胸一线治疗。

要点

  • tPA联合DNase与单用tPA相比,住院时间无显著差异。
  • 次要结局包括退热时间、拔管时间、再入院等均无显著差异。
  • 无死亡病例,两组严重不良事件比例相近。

核心结论

  • 在儿童脓胸中,胸膜腔内tPA联合DNase与tPA联合安慰剂相比,未缩短住院时间,也未改善次要结局。

研究设计与样本

  • 多中心、平行组、安慰剂对照、优效性随机临床试验,纳入6个月至18岁需引流的脓胸患儿,来自6家加拿大三级儿童医院。
  • 共评估379例,排除281例,随机98例,排除1例不符合纳入标准,最终分析97例。
  • 干预组接受胸膜腔内tPA 4 mg后DNase 5 mg,每日3次;对照组接受tPA 4 mg后5 mL生理盐水,每日3次。
  • 受试者、家属、临床人员和研究团队成员均对分组设盲。

主要发现

  • 所有次要结局均无显著差异。
  • tPA联合DNase组14例不良事件中6例(43%)为严重不良事件;tPA联合安慰剂组21例不良事件中8例(38%)为严重不良事件。
  • 无死亡病例。

关键数值与推荐

  • 主要结局为从胸管置入至出院的住院时间。
  • 次要结局包括达到出院标准时间、拔管时间、平均发热持续时间、额外胸膜引流操作、再入院和总医疗费用。

临床怎么用

  • 临床实践指南应继续支持胸管置入联合单用胸膜腔内纤溶药物作为儿童脓胸的一线治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Clinical guidelines recommend that children with pleural empyema be treated with chest tube insertion and intrapleural fibrinolytics. The addition of dornase alfa (DNase) has been reported to improve outcomes in adults but remains unproven in children. OBJECTIVE: To determine if intrapleural tissue plasminogen activator (tPA) and DNase is more effective than tPA and placebo at reducing hospital length of stay in children with pleural empyema. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, parallel-group, placebo-controlled, superiority randomized clinical trial included children diagnosed as having pleural empyema requiring drainage aged 6 months to 18 years treated at 6 tertiary Canadian children's hospitals. A total of 379 children were assessed for eligibility; 281 were excluded and 98 were randomized. One child was excluded after randomization for not meeting the inclusion criteria. Data were collected from March 4, 2013, to December 13, 2017. INTERVENTIONS: Participants underwent chest tube insertion and 3 daily administrations of intrapleural tPA, 4 mg, followed by DNase, 5 mg (intervention group), or 5 mL of normal saline (placebo; control group). Participants, families, clinical staff, and members of the study team were blinded to allocation. MAIN OUTCOMES AND MEASURES: The primary outcome was hospital length of stay from chest tube insertion to discharge. Secondary outcomes included time to meeting discharge criteria, time to chest tube removal, mean fever duration, additional pleural drainage procedures, hospital readmissions, and total health care cost. RESULTS: Of the 97 analyzed children with pleural empyema, 52 (54%) were male, and the mean (SD) age was 5.1 (3.6) years. A total of 49 children were randomized to tPA and DNase and 48 were randomized to tPA and placebo. Treatment with tPA and DNase was not associated with decreased hospital length of stay compared with tPA and placebo (mean [SD] length of stay, 9.0 [4.9] vs 9.1 [5.3] days; mean difference, -0.1 days; 95% CI, -2.0 to 2.1; P = .96). Similarly, no significant differences were observed for any of the secondary outcomes. Of the 14 adverse events in the tPA and DNase group, 6 (43%) were serious; of the 21 adverse events in the tPA and placebo group, 8 (38%) were serious. There were no deaths. CONCLUSIONS AND RELEVANCE: The addition of DNase to intrapleural tPA for children with pleural empyema had no effect on hospital length of stay or other outcomes compared with tPA with placebo. Clinical practice guidelines should continue to support the use of chest tube insertion and intrapleural fibrinolytics alone as first-line treatment for pediatric empyema. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01717742.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Livingston MH, Mahant S, Connolly B, et al. Effectiveness of Intrapleural Tissue Plasminogen Activator and Dornase Alfa vs Tissue Plasminogen Activator Alone in Children with Pleural Empyema: A Randomized Clinical Trial. JAMA Pediatr. 2020. PMID: 32011642. doi:10.1001/jamapediatrics.2019.5863

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。